NASDAQ: DYAI | Healthcare / Biotechnology / USA |
2.64 | -0.0400 | -1.49% | Vol 61.87K | 1Y Perf -49.24% |
Aug 11th, 2022 15:59 DELAYED |
BID | 1.97 | ASK | 3.19 | ||
Open | 2.75 | Previous Close | 2.68 | ||
Pre-Market | - | After-Market | - | ||
- - | - -% |
Target Price | 6.00 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 127.27 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | — - | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 17.45 | Earnings Rating | — | |
Market Cap | 74.62M | Earnings Date | 10th Aug 2022 | |
Alpha | 0.02 | Standard Deviation | 0.17 | |
Beta | 0.26 |
Today's Price Range 2.552.97 | 52W Range 1.746.89 | 5 Year PE Ratio Range -19.70-18.10 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -6.38% | ||
1 Month | -19.27% | ||
3 Months | 26.92% | ||
6 Months | -31.25% | ||
1 Year | -49.24% | ||
3 Years | -53.44% | ||
5 Years | 95.56% | ||
10 Years | 95.56% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -15.76 | |||
ROE last 12 Months | -58.30 | |||
ROA (5Y Avg) | -26.24 | |||
ROA last 12 Months | -52.41 | |||
ROC (5Y Avg) | -18.06 | |||
ROC last 12 Months | -58.44 | |||
Return on invested Capital Q | -14.34 | |||
Return on invested Capital Y | -20.93 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-7.10 | ||||
5.41 | ||||
48.51 | ||||
52.10 | ||||
-10.80 | ||||
-0.44 | ||||
5.41 | ||||
0.58 | ||||
73.31M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
8.80 | ||||
8.90 | ||||
- | ||||
- | ||||
- | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
24.40 | ||||
-543.80 | ||||
-543.80 | ||||
-645.20 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.65M | ||||
0.06 | ||||
15.25 | ||||
28.82 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.09 | -0.12 | -33.33 |
Q01 2022 | -0.09 | -0.09 | 0.00 |
Q04 2021 | -0.04 | -0.15 | -275.00 |
Q03 2021 | -0.10 | -0.06 | 40.00 |
Q02 2021 | -0.09 | -0.14 | -55.56 |
Q03 2020 | -0.08 | -0.09 | -12.50 |
Q02 2020 | -0.05 | -0.10 | -100.00 |
Q01 2020 | -0.02 | -0.08 | -300.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | - |
Estimated EPS Next Report | -0.09 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 61.87K |
Shares Outstanding | 28.26K |
Shares Float | 19.91M |
Trades Count | 291 |
Dollar Volume | 167.84K |
Avg. Volume | 41.22K |
Avg. Weekly Volume | 48.28K |
Avg. Monthly Volume | 38.01K |
Avg. Quarterly Volume | 37.37K |
Dyadic International Inc. (NASDAQ: DYAI) stock closed at 2.64 per share at the end of the most recent trading day (a -1.49% change compared to the prior day closing price) with a volume of 61.87K shares and market capitalization of 74.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 7 people. Dyadic International Inc. CEO is Mark A. Emalfarb.
The one-year performance of Dyadic International Inc. stock is -49.24%, while year-to-date (YTD) performance is -41.59%. DYAI stock has a five-year performance of 95.56%. Its 52-week range is between 1.7419 and 6.89, which gives DYAI stock a 52-week price range ratio of 17.45%
Dyadic International Inc. currently has a PE ratio of -7.10, a price-to-book (PB) ratio of 5.41, a price-to-sale (PS) ratio of 48.51, a price to cashflow ratio of 52.10, a PEG ratio of 2.32, a ROA of -52.41%, a ROC of -58.44% and a ROE of -58.30%. The company’s profit margin is -%, its EBITDA margin is -543.80%, and its revenue ttm is $1.65 Million , which makes it $0.06 revenue per share.
Of the last four earnings reports from Dyadic International Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Dyadic International Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Dyadic International Inc. is Moderate Buy (2), with a target price of $6, which is +127.27% compared to the current price. The earnings rating for Dyadic International Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Dyadic International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Dyadic International Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.61, ATR14 : 0.23, CCI20 : -95.04, Chaikin Money Flow : -0.42, MACD : -0.08, Money Flow Index : 51.60, ROC : -6.38, RSI : 35.61, STOCH (14,3) : 14.06, STOCH RSI : 0.57, UO : 25.41, Williams %R : -85.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Dyadic International Inc. in the last 12-months were: Mark A. Emalfarb (Option Excercise at a value of $244 500), Mark A. Emalfarb (Sold 90 902 shares of value $379 503 ), Ronen Tchelet (Option Excercise at a value of $14 041), Ronen Tchelet (Sold 8 943 shares of value $31 202 ), Seth J. Herbst (Option Excercise at a value of $30 250)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Strong Buy | Strong Buy |
Dyadic International Inc is a biotechnology company engaged in the discovery, development, manufacturing and selling of enzymes and other proteins for the bioenergy, biochemical, industrial enzyme and biopharmaceutical industries.
CEO: Mark A. Emalfarb
Telephone: +1 561 743-8333
Address: 140 Intracoastal Pointe Drive, Jupiter 33477, FL, US
Number of employees: 7
Fri, 13 May 2022 10:35 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: CTI BioPharma (CTIC), Dyadic International (DYAI) and Assembly Biosciences (ASMB)
- TipRanks. All rights reserved.Mon, 02 May 2022 09:04 GMT Analysts Offer Insights on Healthcare Companies: and Dyadic International (DYAI)
- TipRanks. All rights reserved.Tue, 11 Jan 2022 11:17 GMT Dyadic International (DYAI) Receives a Buy from H.C. Wainwright
- TipRanks. All rights reserved.Fri, 07 Jan 2022 09:11 GMT Dyadic International (DYAI) Gets a Buy Rating from Dawson James
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.